A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of Fluzoparib Following Single and Multiple Oral Doses in Patients With Advanced Solid Malignancies

Trial Profile

A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of Fluzoparib Following Single and Multiple Oral Doses in Patients With Advanced Solid Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Fluzoparib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Feb 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Apr 2017.
    • 19 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top